{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:42:59Z","timestamp":1777934579687,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Gemcitabine is a well-tolerated pyrimidine antimetabolite chemotherapeutic that is increasingly utilized to treat non-small cell lung carcinoma, breast, pancreatic, and urogenital cancers. Myelosuppression is a common side effect and skin rashes can be observed. We discuss a case of the exceedingly rare DRESS syndrome, which appeared following Gemcitabine treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>A 60-year-old patient with pancreatic cancer and liver metastases received therapy with Gemcitabine as a single agent. Fever, itching, and redness started to be reported on the third day of receiving Gemcitabine treatment. The patient's diffuse maculopapular rash steadily got worse, leading to hospitalization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management and outcome<\/jats:title>\n                    <jats:p>In the patient's physical examination, a high fever, hepatomegaly, and a diffuse macular papular rash were detected, an increase in eosinophils in the complete blood count and peripheral blood. A skin biopsy was performed. It was determined that the patient had Gemcitabine-associated DRESS syndrome. Antihistamines and local steroids were administered. On the fifth day following treatment, skin lesions and eosinophilia decreased.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The most common cause of DRESS syndrome, a disorder marked by extensive skin eruption, fever, eosinophilia, and systemic symptoms, is medication use. Infections including HHV-6, EBV, and CMV can occasionally be the reason. Gemcitabine is one of the medications that is frequently used in cancer, and a case was provided because the literature review did not mention Gemcitabine-related DRESS syndrome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552231167531","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T03:36:13Z","timestamp":1680492973000},"page":"1480-1483","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Gemcitabine-associated DRESS syndrome: A case report"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8713-7613","authenticated-orcid":false,"given":"Ertugrul","family":"Bayram","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, \u00c7ukurova University Faculty of Medicine, Adana, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tugba","family":"Toyran","sequence":"additional","affiliation":[{"name":"Department of Pathology, \u00c7ukurova University Faculty of Medicine, Adana, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4642-3693","authenticated-orcid":false,"given":"Semra","family":"Paydas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, \u00c7ukurova University Faculty of Medicine, Adana, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,4,3]]},"reference":[{"key":"bibr1-10781552231167531","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199754030-00009"},{"key":"bibr2-10781552231167531","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/54.2.162"},{"key":"bibr3-10781552231167531","doi-asserted-by":"publisher","DOI":"10.2174\/0929867326666190816230650"},{"key":"bibr4-10781552231167531","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.03.063"},{"key":"bibr5-10781552231167531","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj941"},{"key":"bibr6-10781552231167531","doi-asserted-by":"publisher","DOI":"10.1177\/030089160409000206"},{"key":"bibr7-10781552231167531","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.3.491"},{"key":"bibr8-10781552231167531","doi-asserted-by":"publisher","DOI":"10.1517\/14740330802374262"},{"key":"bibr9-10781552231167531","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199803000-00001"},{"key":"bibr10-10781552231167531","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970715)80:2<286::AID-CNCR17>3.0.CO;2-Q"},{"key":"bibr11-10781552231167531","doi-asserted-by":"publisher","DOI":"10.1016\/S1085-5629(96)80038-1"},{"key":"bibr12-10781552231167531","volume":"2011","author":"Cardoso CS","year":"2011","journal-title":"Case Reports"},{"key":"bibr13-10781552231167531","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2012.705828"},{"key":"bibr14-10781552231167531","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(195901\/02)12:1<164::AID-CNCR2820120122>3.0.CO;2-Y"},{"key":"bibr15-10781552231167531","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2013.811588"},{"key":"bibr16-10781552231167531","first-page":"147","volume":"9","author":"Canitez Y","year":"2015","journal-title":"T\u00fcrkiye \u00c7ocuk Hastal\u0131klar\u0131 Dergisi"},{"key":"bibr17-10781552231167531","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12501"},{"key":"bibr18-10781552231167531","unstructured":"Raedler LA. Infugem (Gemcitabine) First Formulation of Premixed, Ready-to-Administer Intravenous Chemotherapy Approved for Several Tumor Types."},{"key":"bibr19-10781552231167531","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231167531","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552231167531","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231167531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:28:10Z","timestamp":1777688890000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552231167531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,3]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1177\/10781552231167531"],"URL":"https:\/\/doi.org\/10.1177\/10781552231167531","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,3]]}}}